Stocks making the biggest premarket moves: Metsera, Compass, Kenvue, Fox & more

Pfizer announced a $4.9 billion cash acquisition of weight-loss drugmaker Metsera, sending Metsera shares up 60% and Pfizer up 3%. Concurrently, real estate giant Compass plans an all-stock $1.6 billion takeover of rival Anywhere, creating a $10 billion enterprise, with Anywhere soaring 50% and Compass dipping 9%. In other news, Kenvue fell 5% on reports linking Tylenol to autism, while Sarepta Therapeutics, Crown Castle, and Applied Materials gained on analyst upgrades, and Fox Corp rose on speculation about TikTok involvement.

Analysis

The pre-market session is characterized by significant M&A activity and specific, catalyst-driven stock movements. In the biopharmaceutical sector, Pfizer is making a strategic entry into the weight-loss drug market with a $4.9 billion all-cash acquisition of Metsera, a move that sent Metsera's stock soaring 60% and lifted Pfizer's by 3%. In real estate, a major consolidation is underway as Compass plans to acquire rival Anywhere in a $1.6 billion all-stock transaction, creating a combined entity with a $10 billion enterprise value; the market reacted predictably, with target Anywhere surging over 50% while acquirer Compass declined 9% on dilution concerns. Elsewhere, Kenvue shares fell 5% following a damaging report linking its Tylenol product to autism, introducing significant headline and potential litigation risk. Conversely, analyst upgrades provided a tailwind for Sarepta Therapeutics, which climbed 6% on a BMO upgrade citing a favorable risk/reward, and for Crown Castle and Applied Materials, which rose 1.1% and over 1% respectively on valuation-based upgrades. Finally, Fox Corp shares gained nearly 4% on speculative reports of its involvement in a potential deal for TikTok's U.S. operations.

Key Decisions for Investors

• View Pfizer's $4.9B cash acquisition of Metsera as a strong strategic positive, bolstering its pipeline in the lucrative weight-loss market, but recognize that the arbitrage opportunity in Metsera stock is now largely captured.
• Consider the 9% dip in Compass shares as a potential entry point for a long-term position, contingent on belief in the synergies from the Anywhere merger, while acknowledging the inherent execution and dilution risks of the all-stock deal.
• Investors in Kenvue should monitor for further developments regarding the reported Tylenol-autism link, as the 5% drop indicates significant headline risk and potential for future litigation that could pressure the stock further.
• Re-evaluate positions in Sarepta Therapeutics, Crown Castle, and Applied Materials, as recent analyst upgrades citing attractive valuations and favorable risk/reward profiles may signal a positive sentiment shift and upcoming reassessment by the market.
• Treat the 4% gain in Fox Corp as highly speculative and event-driven, tied to unconfirmed reports of a TikTok deal, and manage positions accordingly based on risk tolerance for binary outcomes.